Drug Profile
Cytomegalovirus vaccine - GSK
Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Cytomegalovirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 22 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 05 Jan 2000 Profile reviewed but no significant changes made
- 18 Oct 1999 Ribi ImmunoChem has been integrated into Corixa Corporation